The US FDA gave its blessing to Inspirion Delivery Sciences LLC's immediate-release (IR) opioid RoxyBond (oxycodone hydrochloride), making it the first IR opioid with abuse-deterrent language in the labeling, but the incorporation of a Risk Evaluation and Mitigation Strategy (REMS) could still be at least a few months away.
The company announced the approval of RoxyBond April 26 with the indication for the management of pain severe enough to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?